Physician profile
Jonathan Musmand
NPI 1982652707
$239,240.22
in general payments reported to CMS, 2019-2025
32 companies · $68K in 2025
The $68K reported for 2025 was more than what 96% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $436 · 2020: $13K · 2021: $12K · 2022: $37K · 2023: $53K · 2024: $56K · 2025: $68K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $146K · Food and Beverage: $14K · Travel and Lodging: $12K · Consulting Fee: $4,967 · Education: $46.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $145,973.00 |
| Food and Beverage | $14,134.35 |
| Travel and Lodging | $11,687.84 |
| Consulting Fee | $4,966.50 |
| Education | $46.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $92,995.17 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Regeneron Healthcare Solutions, INC. | $82,582.50 | 2020-2025 | Dupixent |
| Genzyme Corporation | $50,512.83 | 2019-2025 | |
| Csl Behring | $6,632.12 | 2020-2025 | Andembry, Haegarda, Hizentra |
| Glaxosmithkline, LLC. | $1,526.29 | 2019-2025 | Trelegy Ellipta, Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $1,114.06 | 2021-2025 | Cuvitru, Eohilia, Takhzyro |
| Amgen INC. | $738.08 | 2021-2025 | Tezspire, Actimmune |
| Novartis Pharmaceuticals Corporation | $633.15 | 2020-2025 | |
| Pfizer INC. | $414.67 | 2020-2025 | |
| Biocryst US Sales Co., LLC | $388.30 | 2021-2025 | Orladeyo |
| Pharming Healthcare, INC. | $320.17 | 2022-2025 | Ruconest |
| Grifols USA, LLC | $166.84 | 2019-2024 | Xembify, Prolastin-C Liquid |
| Blueprint Medicines Corporation | $150.74 | 2021-2024 | Ayvakit |
| Teva Pharmaceuticals USA, INC. | $120.65 | 2020-2021 | |
| Mylan Specialty L.P. | $97.49 | 2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $93.74 | 2025 | Ebglyss, Taltz |
| Ars Pharmaceuticals Operations, INC. | $91.29 | 2025 | Neffy |
| Merck Sharp & Dohme LLC | $85.18 | 2022-2025 | Capvaxive, Enflonsia |
| Phadia US INC. | $83.20 | 2022 | |
| Invivyd INC | $62.22 | 2025 | Pemgarda |
| Verona Pharma, INC. | $53.18 | 2025 | Ohtuvayre |
| Ionis Pharmaceuticals, INC. | $49.06 | 2025 | |
| Abbvie INC. | $45.28 | 2022-2023 | |
| Aimmune Therapeutics, INC. | $43.71 | 2020 | |
| Incyte Corporation | $40.18 | 2022-2023 | Opzelura |
| Kaleo, INC. | $39.39 | 2020-2022 | |
| Horizon Therapeutics Plc | $38.30 | 2020-2023 | Actimmune |
| Galderma Laboratories, L.P. | $33.93 | 2025 | Nemluvio |
| X4 Pharmaceuticals, INC. | $30.96 | 2024 | Xolremdi |
| Paratek Pharmaceuticals, INC. | $20.52 | 2025 | Xhance |
| Genentech USA, INC. | $19.02 | 2025 | Xolair |
| Uswm, LLC | $18.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Musmand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.